Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis

Piccoli, Leonora De Zorzi; Mattos, Angelo Alves de; Coral, Gabriela Perdomo; Mattos, Ângelo Zambam de; Santos, Diogo Edele dos.
Arq. gastroenterol ; 48(3): 179-185, July-Sept. 2011. tab
Artículo en Inglés | LILACS | ID: lil-599650

Documentos relacionados

  1. Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases.
  2. Association of <i>IFNL3</i> Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.
  3. Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-&#945;(2a) monotherapy.
  4. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
  5. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
  6. Hepatitis C virus diversity and hepatic steatosis.
  7. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.
  8. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
  9. Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus.
  10. [Hepatitis C virus genotype 3: that simple, yet that complex (corrected)].